10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
GlaxoSmithKline has announced it will begin shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2019-20 flu season. 16 July 2019
Seqirus, a global leader in influenza prevention and part of Australia’s CSL Limited, announced today it is first-to-market with shipping its portfolio of seasonal influenza vaccines to customers in the USA for the 2019/20 influenza season. 15 July 2019
German privately-held drugmaker Boehringer Ingelheim has bought Swiss biotech firm AMAL Therapeutics for up to 326 million euros ($366 million). 15 July 2019
AbbVie today revealed it has bought Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer. 15 July 2019
Australian clinical-stage immuno-oncology company Imugene today announced that it would acquire Vaxinia Pty Ltd via a cash and share deal valued at A$1.619 million ($1.13 billion). 15 July 2019
British medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has published a positive Final Appraisal Document (FAD), confirming that Skyrizi (risankizumab) is recommended for the treatment of severe psoriasis in adult patients who have failed conventional systemic therapies. 15 July 2019
The B-cell non-Hodgkin’s lymphoma (NHL) market is expected to grow from $5.7 billion in 2017 to $9.2 billion by 2027 across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan) at a compound annual growth rate (CAGR) of 4.9%. 15 July 2019
In a deal revealed late Sunday, Galapagos is set to receive upfront payments and an equity investment of more than $5 billion from US biotech major Gilead Sciences. 15 July 2019
The Düsseldorf Regional Court has found that Praluent (alirocumab) infringes the German part of US biotech firm Amgen’s European patent (EP 2 215 124), relating to rival product Repatha (evolocumab), directed to antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). 15 July 2019
Maryland, USA-based biotech Altimmune (Nasdaq: ALT) has entered into an agreement to acquire Spitfire Pharma in a cash and stock deal worth up to $93 million. 13 July 2019
A new report from Boston, USA-based cost-effectiveness watchdog The Institute for Clinical and Economic Review (ICER) will make difficult reading for Duchenne muscular dystrophy (DMD) therapy manufacturers. 12 July 2019
US biotech major Gilead Sciences has lured high pharma profile Christi Shaw to the company as chief executive of CAR-T cancer therapy specialist Kite. 12 July 2019
In yet another setback in the quest for Alzheimer’s therapies it was decided to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase II/III studies in the Alzheimer's Prevention Initiative Generation Program. 12 July 2019
US RNAi therapies specialist Alnylam yesterday announced that Jeff Poulton joined the company on July 11, 2019, and has been appointed executive vice president and chief financial officer (CFO), effective August 13. 12 July 2019
Scientists discovered that when the breast cancer drug palbociclib was combined with the lung cancer drug crizotinib, the two-drug combination was significantly more effective against cancer cells in the laboratory than either drug used on its own. 12 July 2019
US biotech start-up Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences to develop and commercialize ultra-long-acting oral HIV therapies. 10 July 2019
A bid from France’s Sanofi to market the anti-CD38 therapy isatuximab will be reviewed by the US regulator, with a decision expected by April 30, 2020. 10 July 2019
San Diego, USA based biotech Mirati Therapeutics has entered a clinical collaboration agreement with Swiss pharma giant Novartis to investigate a combination therapy for solid tumors. 10 July 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024